Skip to main content
SpringerLink
Log in

Rivastigmine in Parkinson’s Disease Dementia

Profile Report

  • Adis Profile Report
  • Published:
Drugs & Aging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Siddiqui MA, Wagstaff AJ. Rivastigmine: in Parkinson’s disease dementia. CNS Drugs 2006; 20(9): 739–47

    Article  PubMed  CAS  Google Scholar 

  2. Emre M. Rivastigmine in Parkinson’s disease dementia: a viewpoint. CNS Drags 2006; 20(9): 748

    Article  Google Scholar 

  3. Poewe W. Rivastigmine in Parkinson’s disease dementia: a viewpoint. CNS Drags 2006; 20(9): 748–49

    Article  Google Scholar 

  4. Aarsland D. Rivastigmine in Parkinson’s disease dementia: a viewpoint. CNS Drags 2006; 20(9): 749–50

    Google Scholar 

  5. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006 Apr 2; 66(7): 996–1002

    Article  PubMed  CAS  Google Scholar 

  6. Levy G, Schupf N, Tang MX, et al. Combined effect of age and severity on the risk of dementia in Parkinson’s disease. Ann Neurol 2002; 51(6): 722–9

    Article  PubMed  Google Scholar 

  7. Camicioli R, Fisher N. Progress in clinical neurosciences: Parkinson’s disease with dementia and dementia with Lewy bodies. Can J Neurol Sci 2004; 31(1): 7–21

    PubMed  Google Scholar 

  8. Burn DJ, McKeith IG. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson’s disease. Mov Disord 2003 Sep; 18Suppl. 6: S72–9

    Article  PubMed  Google Scholar 

  9. Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology 2001 Mar; 56(6): 730–6

    Article  PubMed  CAS  Google Scholar 

  10. Williams-Gray CH, Foltynie T, Lewis SJG, et al. Cognitive deficits and psychosis in Parkinson’s disease: a review of pathophysiology and therapeutic options. CNS Drags 2006; 20(6): 477–505

    Article  CAS  Google Scholar 

  11. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003 Mar; 60(3): 387–92

    Article  PubMed  Google Scholar 

  12. Braak H, Rub U, Jansen Steur EN, et al. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005 Apr 26; 64(8): 1404–10

    Article  PubMed  CAS  Google Scholar 

  13. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003 Dec; 60(12): 1745–8

    Article  PubMed  Google Scholar 

  14. Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1985 May; 48(5): 413–21

    Article  PubMed  CAS  Google Scholar 

  15. Mesulam MM, Guillozet A, Shaw P, et al. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 2002 Apr; 110(4): 627–39

    Article  PubMed  CAS  Google Scholar 

  16. Greig NH, Utsuki T, Ingram DK, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent. Proc Natl Acad Sci U S A 2005 Nov; 102(47): 17213–8

    Article  PubMed  CAS  Google Scholar 

  17. Perry E, McKeith I, Ballard C. Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology 2003 Jun 10; 60(11): 1852–3

    Article  PubMed  Google Scholar 

  18. Spencer CM, Noble S. Rivastigmine: a review of its use in Alzheimer’s disease. Drugs Aging 1998 Nov; 13(5): 391–410

    Article  PubMed  CAS  Google Scholar 

  19. Plosker GL, Keating GM. Management of mild to moderate Alzheimer disease: defining the role of rivastigmine. Dis Manage Health Outcome 2004; 12(1): 55–72

    Article  CAS  Google Scholar 

  20. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004 Dec 9; 351(24): 2509–18

    Article  PubMed  CAS  Google Scholar 

  21. Wesnes KA, McKeith I, Edgar C, et al. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005 Nov 22; 65(10): 1654–6

    Article  PubMed  CAS  Google Scholar 

  22. Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease: an active treatment extension study. Mov Disord 2006 Apr; 21(4): 456–61

    Article  PubMed  Google Scholar 

  23. Ballard C, Lane R, Barone P, et al. Cardiac safety of rivastigmine in Lewy body and Parkinson’s disease dementias. Int J Clin Pract 2006 Jun; 60(6): 639–45

    Article  PubMed  CAS  Google Scholar 

  24. Novartis Europharm Limited. Product information (EU): Exelon® (rivastigmine tartarate) capsules and oral solution [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/exelon/exelon.htm [Accessed 2006 May 25]

  25. Poewe WH, Wenning GK. The natural history of Parkinson’s disease. Ann Neurol 1998 Sep; 44 (3 Suppl. 1): Sl–9

    Google Scholar 

  26. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 2005 Oct; 20(10): 1255–63

    Article  PubMed  Google Scholar 

  27. Hely MA, Morris JG, Reid WG, et al. Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005 Feb; 20(2): 190–9

    Article  PubMed  Google Scholar 

  28. Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson’s disease: an evidence based assessment. Lancet 2002 May 4; 359(9317): 1589–98

    Article  PubMed  Google Scholar 

  29. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000 Dec 16; 356(9247): 2031–6

    Article  PubMed  CAS  Google Scholar 

  30. Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson’s disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004 Sep; 17(3): 164–71

    Article  PubMed  Google Scholar 

  31. Perry EK, Kilford L, Lees AJ, et al. Increased Alzheimer pathology in Parkinson’s disease related to antimuscarinic drugs. Ann Neurol 2003 Aug; 54(2): 235–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wolters Kluwer Health | Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    M. Asif A. Siddiqui & Antona J. Wagstaff

  2. editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

    M. Asif A. Siddiqui & Antona J. Wagstaff

Authors
  1. M. Asif A. Siddiqui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antona J. Wagstaff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Asif A. Siddiqui.

Additional information

Adapted and reproduced from CNS Drugs 2006; 20 (9): 739–750.[1–4] The manufacturer of the agent under review was offered an opportunity to comment on the original article[1] during the peer review process; changes based on any comments received were made on the basis of scientific and editorial merit.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siddiqui, M.A.A., Wagstaff, A.J. Rivastigmine in Parkinson’s Disease Dementia. Drugs Aging 24, 255–259 (2007). https://doi.org/10.2165/00002512-200724030-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200724030-00006

Keywords

Search

Navigation